Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,823 across all filing types
Latest filing 2019-08-30 Foreign Filer Report
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
6-K
Foreign Filer Report
2019-08-30 English
Ofatumumab Demonstrates Superiority Versus Teriflunomide in Two Head-to-Head Phase III Multiple Sclerosis Studies
Regulatory Filings Classification · 95% confidence The document is a 'Company Announcement' from Genmab A/S regarding positive Phase III clinical trial results for ofatumumab. It provides a summary of the study findings, the company's outlook, and contact information. Crucially, the document explicitly labels itself as 'Company Announcement no. 43' and includes an 'Attachment' section at the bottom with a link to download the full report. Following the 'Menu vs Meal' rule, since this is a short announcement (under 5,000 characters of core content excluding boilerplate/references) that explicitly points to an attached report, it is classified as a Report Publication Announcement (RPA).
2019-08-30 English
Ofatumumab Demonstrates Superiority Versus Teriflunomide in Two Head-to-Head Phase III Multiple Sclerosis Studies
Regulatory Filings Classification · 95% confidence The document is a 'Company Announcement' from Genmab A/S regarding positive Phase III clinical trial results for ofatumumab. It provides a summary of the study findings, the company's outlook, and contact information. Crucially, the document explicitly labels itself as 'Company Announcement no. 43' and includes an 'Attachment' section at the bottom with a link to download the full report. Following the 'Menu vs Meal' rule, since this is a short announcement (under 5,000 characters of core content excluding boilerplate/references) that explicitly points to an attached report, it is classified as a Report Publication Announcement (RPA).
2019-08-30 English
Ofatumumab Demonstrates Superiority Versus Teriflunomide in Two Head-to-Head Phase III Multiple Sclerosis Studies
Regulatory Filings Classification · 95% confidence The document is a 'Company Announcement' from Genmab A/S regarding positive Phase III clinical trial results for ofatumumab. It provides a summary of the study findings, the company's outlook, and contact information. Crucially, the document explicitly labels itself as 'Company Announcement no. 43' and includes an 'Attachment' section at the bottom with a link to download the full report. Following the 'Menu vs Meal' rule, since this is a short announcement (under 5,000 characters of core content excluding boilerplate/references) that explicitly points to an attached report, it is classified as a Report Publication Announcement (RPA).
2019-08-30 English
Ofatumumab Demonstrates Superiority Versus Teriflunomide in Two Head-to-Head Phase III Multiple Sclerosis Studies
Regulatory Filings Classification · 95% confidence The document is a 'Company Announcement' from Genmab A/S regarding positive Phase III clinical trial results for ofatumumab. It provides a summary of the study findings, the company's outlook, and contact information. Crucially, the document explicitly labels itself as 'Company Announcement no. 43' and includes an 'Attachment' section at the bottom with a link to download the full report. Following the 'Menu vs Meal' rule, since this is a short announcement (under 5,000 characters of core content excluding boilerplate/references) that explicitly points to an attached report, it is classified as a Report Publication Announcement (RPA).
2019-08-30 English
Ofatumumab Demonstrates Superiority Versus Teriflunomide in Two Head-to-Head Phase III Multiple Sclerosis Studies
Regulatory Filings Classification · 99% confidence The document is titled "Company Announcement" and details positive Phase III clinical trial results (ASCLEPIOS I and II) for the drug ofatumumab, including key efficacy and safety endpoints. It explicitly states that the partner, Novartis, plans to initiate submissions to health authorities by the end of 2019. The document is a press release announcing significant corporate and clinical development news, rather than a formal regulatory filing like a 10-K, an earnings release (ER), or a detailed management discussion (MDA). Since it is a general announcement of material information that doesn't fit the specific categories like ER, CT, or DIV, it falls best under the general Regulatory Filings/Announcements category, which is RNS, as it is a broad press release about corporate developments.
2019-08-30 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.